GLP-1 weight loss drugs: An overview and update
![pharmaphorum podcast episode 97](/sites/default/files/styles/x_large/public/2023-09/pharmaphorum_podcast-Episode-97.jpg?itok=iZ9CU0oI)
GLP-1 agonists like Ozempic, Wegovy, and Mounjaro are dramatically changing the field of medically-assisted weight loss. Dubbed "miracle drugs" by some, these new treatments are staggering in their effectiveness. But, as with any new treatment modality, others are urging caution with a class of drugs that are still not fully understood.
On today’s pharmaphorum podcast, Dr.Tim Church, chief medical officer at digital weight loss clinic Wondr Health, joins editor-in-chief Jonah Comstock to chat about these new drugs, how they work, and how they're changing the game for patients.
Tim and Jonah get into the complex and quaint origin story of these new drugs, some of the concerns around them, and how the unique stigma around obesity has affected the rollout and public perception of these new treatments. They also talk about the important role fitness and lifestyle changes still have to play even with these new drugs in the picture.
If you’ve been following this story or are just now catching wind of it, tune in for a primer and an interesting discussion.
You can listen to episode 97 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, acast, Stitcher, and Podbean.